ANA
LLUCH HERNANDEZ
EMÉRITO/A UNIVERSIDAD
Memorial Sloan Kettering Cancer Center
Nueva York, Estados UnidosPublicacións en colaboración con investigadores/as de Memorial Sloan Kettering Cancer Center (6)
2021
-
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
npj Breast Cancer, Vol. 7, Núm. 1
2018
-
Primary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study)
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii90
2015
-
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration
Annals of Oncology, Vol. 26, Núm. 7, pp. 1280-1291
2014
-
MicroRNA profile in very young women with breast cancer
BMC Cancer, Vol. 14, Núm. 1
-
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
The Lancet Oncology, Vol. 15, Núm. 6, pp. 640-647
-
Predicting response and survival in chemotherapy-treated triple-negative breast cancer
British Journal of Cancer, Vol. 111, Núm. 8, pp. 1532-1541